Maravai lifesciences (mrvi) reports weak q4, faces investor class action – hagens berman

San francisco, april 18, 2025 (globe newswire) -- maravai lifesciences holdings, inc. (nasdaq: mrvi) reported its fourth-quarter 2024 earnings, missing analyst expectations and prompting a significant downward revision of its price target by at least one firm. the company is also facing a securities class action lawsuit alleging improper accounting.
ATKR Ratings Summary
ATKR Quant Ranking